Take part in a paid clinical trial

We’re currently looking for adults aged 18 to 65 who are experiencing androgenetic alopecia (AGA), also known as pattern hair loss, to take part in The Headline Trial.

Hair loss is common and can affect both men and women. This clinical study is investigating new approaches that may help shape future treatment options.

You don’t need a formal diagnosis to get started. If you think you may have AGA, you can begin with a quick pre-screen. This helps us assess whether you may meet the initial study requirements. Completing the pre-screen doesn’t guarantee enrolment, but it’s an important first step in seeing whether the study may be suitable for you.

By getting involved, you’ll be contributing to research that aims to improve future options for people affected by hair loss.

This clinical trial is sponsored by a pharmaceutical company. It is investigating a potential drug (the study drug) for inflammatory and fibrotic conditions. These include long-term digestive diseases such as ulcerative colitis and Crohn’s disease, where ongoing inflammation and scarring can damage the intestines. Some current treatments may not work for everyone and can cause significant side effects. This trial is designed to assess the safety and potential benefits of an investigational study drug that may offer an additional option for people who do not respond well to existing therapies. This trial is being held in Brisbane.

We are conducting a clinical trial to explore a potential new treatment for weight management and metabolic disorders. This treatment is being developed to support healthy weight loss while helping the body maintain lean muscle mass, which plays an important role in long-term weight maintenance. Through this study, we hope to better understand whether this new approach can provide a safe and effective option for people who may benefit from additional support with managing their weight. By joining the trial, you’ll be contributing to important research that could help improve weight management options in the future.

This study is testing a new drug that is being developed to help people with inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease. While there are treatments already available, many of them only target one part of the immune system and don’t fully address all aspects of the disease. For example, current therapies often don’t treat the scarring (called fibrosis) that can build up in the bowel over time, and they may not fully heal the lining of the gut. Some treatments also stop working after a while or cause side effects that make long-term use difficult.